The earnings miss is secondary to the pipeline catalyst timeline. Monitor for REVEAL pivotal trial topline data and FDA feedback in 1H 2027, which will determine TSHA-102's BLA path. The $230M cash raise removes near-term dilution risk but increases the binary outcome sensitivity to the pivotal data.
Price Chart
Executive Summary
Taysha Gene Therapies reported Q2 2026 EPS of -$0.13, missing consensus of -$0.11 by 18.2%, with zero revenue vs. $1.99M a year ago. The miss is overshadowed by completion of dosing in the pivotal REVEAL trial and a $230M follow-on offering extending cash runway into 2H 2028, with topline data and FDA feedback expected in 1H 2027. The stock's reaction will hinge on pipeline catalysts, not the quarterly financials.
Key Financial Metrics
Key Facts
- Completed dosing in REVEAL pivotal trial (17 patients) and ASPIRE trial (4 patients) for TSHA-102 in Rett syndrome.
- Topline data from 6-month interim analysis and FDA feedback on BLA pathway expected in 1H 2027.
- Completed $230M follow-on offering; cash and equivalents of $455.4M extend runway into 2H 2028.
- Q2 2026 net loss of $46.6M ($0.13/share) vs. consensus EPS of -$0.11; revenue was $0 vs. $1.99M in Q2 2025.
- TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across 33 patients.
Financial Impact
Q2 2026 net loss of $46.6M vs. $26.9M in Q2 2025; cash burn rate increased due to BLA-enabling manufacturing and clinical trial costs.
Risk Factors
- TSHA-102 pivotal trial data may fail to meet primary endpoint, jeopardizing BLA submission.
- Regulatory feedback from FDA could require additional trials, delaying approval and increasing costs.
- Cash runway into 2H 2028 assumes no further delays; any setback could necessitate additional dilutive financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343130 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Press Release | $6.41 $5.16 | ▼ −19.44% | ▼ −17.54% | $4.66 (−27.17%) |
Jun 25, 2026 14w ago | 8-K | $6.34 $5.83 | ▼ −8.04% | ▼ −9.30% | $4.66 (−26.42%) |
Jun 25, 2026 14w ago | 424B5 | $6.34 $5.83 | ▲ +8.04% | ▲ +9.30% | $4.66 (+26.42%) |
Jun 25, 2026 14w ago | Press Release | $6.21 $5.83 | ▲ +6.12% | ▲ +6.65% | $4.66 (+24.88%) |
Jun 5, 2026 17w ago | Press Release | $5.50 $6.38 | ▲ +16.00% | ▲ +14.14% | $4.66 (−15.18%) |
May 6, 2026 21w ago | 8-K | $6.98 $5.55 | ▼ −20.49% | ▼ −23.27% | $4.66 (−33.17%) |
May 6, 2026 21w ago | Press Release | $6.98 $5.55 | ▼ −20.49% | ▼ −23.27% | $4.66 (−33.17%) |
Apr 29, 2026 22w ago | Press Release | $6.27 $5.75 | ▼ −8.29% | ▼ −13.75% | $4.66 (−25.60%) |
Apr 27, 2026 22w ago | Press Release | $6.30 $5.59 | ▼ −11.27% | ▼ −16.74% | $4.66 (−25.95%) |
Apr 22, 2026 23w ago | DEFA14A | $6.72 $5.19 | ▼ −22.84% | ▼ −26.01% | $4.66 (−30.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access